YẾU TỐ LIÊN QUAN ĐẾN TÌNH TRẠNG KHÔNG ĐÁP ỨNG VỚI SECUKINUMAB Ở BỆNH NHÂN VIÊM CỘT SỐNG DÍNH KHỚP

Abstract

Objectives: Identification of some factors associated with non-response to secukinumab in patients with ankylosing spondylitis. Subjects and methods: Descriptive, Retrospective combined with prospective study in 66 patients received secukinumab medication in Rheumatology Department at Bach Mai Hospital from January 2019 to January 2022. Results: Out of a total of 66 patients participating in the study, there were 19 non-responders (28,8%), 5 of which were primary non–responders (7,6%) and 14 were secondary non-responders (21,2%). There was a correlation between poor responses and patients nonadherence to treatment. Non-adherent patients will have a higher rate of secondary nonresponsiveness to medication compared with compliant patients (p < 0,05). Conclusion: Secukinumab was highly effective in the treatment of Ankylosing Spondylitis but 28,8% of patients was no response. Non-responsiveness to medication was higher in the non-adherent group. Therefore, in order to achieve the best treatment effect, patients with Ankylosing Spondylitis need to be consulted by medical staff about disease progression, treatment plan and long-term follow-up to help patients better adhere to treatment.